SYNEOS HEALTH BA LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Forvis Mazars LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The director has prepared the financial statements on a going concern basis. The Group is in a net current asset and net asset position and the underlying trading of the group (before intangible asset amortisation) will continue to be profitable going forward. Additionally, the company and group have long-term relationships with a number of customers and suppliers across different geographic areas. The ultimate parent company Star Intermediate Holdings, Inc, has assured the director of the provision of financial support if required, in the form of a letter of support for a period of at least 12 months from the approval of the accounts. The director has also assessed that Star Intermediate Holdings, Inc. has sufficient funds to support the Group and Company as required. Accordingly, the accompanying financial statements have been prepared on the assumption that the Group and Company will continue as a going concern.”

Group structure

1. SYNEOS HEALTH BA LIMITED · parent
   1. Illingworth Research Group Limited 100% · United Kingdom · clinical development services to the pharmaceutical, biotechnology and medical device industries
   2. Illingworth Research Group (Australia) PTY Ltd 100% · Australia · clinical development services to the pharmaceutical, biotechnology and medical device industries
   3. Illingworth Research Group (Spain) Sociedad Limitada 100% · Spain · clinical development services to the pharmaceutical, biotechnology and medical device industries
   4. Illingworth Research Group (France) SARL 100% · France · clinical development services to the pharmaceutical, biotechnology and medical device industries
   5. Illingworth Research Group (Italy) S.R.L. 100% · Italy · clinical development services to the pharmaceutical, biotechnology and medical device industries

Significant events

• “On the 28 September 2023 Syneos Health, Inc. completed its transaction to be acquired by a consortium of private investment firms composed of Elliott Investment Management, Patient Square Capital and Vertitas Capital. As a result shares of Syneos Health common stock were removed from listing on the Nasdaq Stock Market. Outstanding awards were converted to contingent cash awards on the date of the transaction.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -5.8%

  £28,174,734 → £26,526,812

• Cash

  -84.8%

  £2,691,970 → £410,080

• Net assets

  -17.7%

  £43,995,438 → £36,206,850

• Employees

  -18.2%

  176 → 144

• Operating profit

  -42.2%

  -£3,549,827 → -£5,046,734

• Profit before tax

  -48.4%

  -£3,313,896 → -£4,918,826

• Wages

  -10.4%

  £6,083,042 → £5,451,426

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers